Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

AbbVie Inc. (ABBV) vs Gilead Sciences, Inc. (GILD)

AbbVie Inc. and Gilead Sciences, Inc. are both Drug Manufacturers General companies. AbbVie Inc. is the larger, with a market value of $467.4B against $183.2B — 2.6× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; AbbVie Inc. trades at 74.7×. AbbVie Inc. grew revenue faster over the last twelve months: 10.4% against 5.52%. AbbVie Inc. has the higher net margin (9.74% vs −10.6%) and the higher return on invested capital (18.1% vs −4.48%). Both pay a dividend; Gilead Sciences, Inc. yields more (4.27% vs 3.57%). Across the 21 metrics below, Gilead Sciences, Inc. leads on 12 and AbbVie Inc. on 9.

Valuation

Metric ABBV GILD Drug Manufacturers General median
P/E 74.67 n/m 24.72
P/S 7.26 6.16 3.35
P/B n/m 15.97 5.00
Price to free cash flow 25.68 14.49 17.68
EV/EBITDA 20.79 804.10 13.91
EV/Sales 8.26 6.92 3.95
Earnings yield 1.34% (1.72%) 2.92%
Free cash flow yield 3.89% 6.90% 4.42%

Profitability

Metric ABBV GILD Drug Manufacturers General median
Gross margin 71.48% 79.59% 72.77%
Operating margin 26.20% (8.20%) 18.90%
Net margin 9.74% (10.64%) 8.27%
Free cash flow margin 28.28% 42.50% 17.25%
Return on equity (208.10%) (20.68%) 6.97%
Return on assets 4.61% (6.17%) 2.76%
Return on invested capital 18.07% (4.48%) 6.30%

Growth

Metric ABBV GILD Drug Manufacturers General median
Revenue growth (TTM) 10.39% 5.52% 6.79%
EPS growth (last fiscal year) (1.26%) 1,684.21% —
Revenue growth, 5-year CAGR 5.95% 3.58% 3.98%
Net income growth, 5-year CAGR (1.94%) 133.35% 0.42%

Health

Metric ABBV GILD Drug Manufacturers General median
Debt to equity (12.03) 2.23 0.63
Current ratio 0.81 1.27 1.32
Net debt to EBITDA 2.59 1.35 1.15

Dividend

Metric ABBV GILD Drug Manufacturers General median
Dividend yield 3.57% 4.27% 3.57%
Payout ratio 1.19 0.68 0.53

Size

Metric ABBV GILD Drug Manufacturers General median
Market cap 467.37b 183.22b 125.91b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack